Clinical Trial Update: Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX [Phase 2]

View source ↗

Summary

Phase II trial evaluating the combination of aprepitant and palonosetron for prevention of chemotherapy-induced nausea and vomiting in colorectal cancer patient…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Nausea and Vomiting
• Colorectal Cancer

Drugs mentioned

• Aloxi (palonosetron hydrochloride)
• EMEND (aprepitant)

Snippet

Sponsor: OHSU Knight Cancer Institute | Conditions: Colorectal Cancer, Nausea and Vomiting | Phase 2 | Status: COMPLETED | Results posted: 2011-08-10